Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S304000, C564S017000, C564S026000, C564S225000, C562S439000, C562S440000, C560S019000, C514S534000, C514S585000, C514S631000
Reexamination Certificate
active
09890990
ABSTRACT:
A compound for use in inducing necrosis in vascular tissue of a tumor in an animal. The compound contains a first moiety which is a cis-stilbene moiety and a second moiety which is an inhibitor of the formation or action of nitric acid. Also, a method for inducing necrosis in vasculature of a tumor in an animal by administering to the animal the compound in an amount effective for inducing the necrosis.
REFERENCES:
patent: 0641767 (1995-03-01), None
patent: 92/16486 (1992-10-01), None
Ohsumi, Koji, et al. “Novel Combretastain Analogues Effective against Murine Solid Tumors: Design and Structure-Activity Relationships” J. Med. Chem. (1998) vol. 41, No. 16 pp. 3022-3032.
Ohsumi, Koji, et al. “Syntheses and Antitumor Activity of Cis-Restricted Combretastatins: 5-Membered Heterocyclic Analogues.” Bioorg. Med. Chem. Lett 8 (1998) pp. 3153-3158.
Pettit, George R., et al. “Antineoplastic agents 322. Synthesis of Combretastatin A-4 prodrugs” Anti-Cancer Drug Design (1995) vol. 10, No. 4 pp. 299-309.
Folkman, Judah, “Clinical Applications of Research on Angiogenesis” Seminars in Medicine of the Beth Israel Hospital, Boston (1995) vol. 333 No. 26 pp. 1757-1763.
Dark, Graham G., et al. “Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity toward Tumor Vasculature1” Cancer Research (1997) vol. 57 pp. 1829-1834.
Chinje, E.C., et al., “Role of nitric oxide in growth of solid tumours: a balancing act”Essays in Biochemistry, vol. 32, pp. 61-72 (1997).
Angiogene Pharmaceuticals Ltd.
Aulakh Charanjit S.
Ladas and Parry LLP
LandOfFree
Substituted stilbene compounds with vascular damaging activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted stilbene compounds with vascular damaging activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted stilbene compounds with vascular damaging activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794399